Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 35,388 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Knowledge, Attitudes, Practice
Interventions: Training Intervention; Behavioral
Lead sponsor: Boston College; Other
Eligibility: 12 Years and older
Enrollment: 286 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Conditions: Alzheimer's Disease
Interventions: Atorvastatin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 40
States / cities: Sun City, Arizona • Fresno, California • Laguna Hills, California + 35 more

Conditions: Parkinson Disease
Interventions: exercise+multi-modal sensory feedback (MMSF), Exercise only; Behavioral
Lead sponsor: Regis University; Other
Eligibility: 21 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Diplopia, Binocular Vision Suppression, Binocular; Fusion, With Defective Stereopsis, Monocular Diplopia
Interventions: Binocular visual confusion (unilateral opaque), Unilateral monocular visual confusion (unilateral see-through), Bilateral monocular visual confusion (bilateral see-through); Behavioral
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 14 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sarcopenia
Interventions: Astaxanthin formulation, Placebo, Exercise training; Other
Lead sponsor: Astavita, Inc.; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Metastatic Melanoma, Skin Cancer
Interventions: Fludarabine, Cyclophosphamide, Aldesleukin, MART-1 Reactive CD8+ PBL; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cell Migration, Cell Invasion, Exercise Recovery
Interventions: Melatonin, Placebo; Dietary Supplement
Lead sponsor: University of Central Florida; Other
Eligibility: 18 Years to 40 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Iron Deficiency Anemia
Interventions: IOP Injection / MPB-1514; Drug
Lead sponsor: MegaPro Biomedical Co. Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 8
States / cities: Azusa, California • Northridge, California • Whittier, California + 5 more

Conditions: Systemic Lupus Erythematosus
Interventions: Mosunetuzumab, Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Anniston, Alabama

Conditions: Pulmonary Arterial Hypertension
Interventions: Placebo, FK506 level < 2 ng/ml, FK506 level 2-3 ng/ml, FK506 level 3-5 ng/ml; Drug
Lead sponsor: Edda Spiekerkoetter; Other
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Congenital Bleeding Disorder, Haemophilia B
Interventions: nonacog beta pegol; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Cincinnati, Ohio • Portland, Oregon • Richmond, Virginia

Conditions: Clostridium Difficile Infection Recurrence
Interventions: FMT oral capsule, Oral Vancomycin, FMT oral placebo, Oral Vancomycin placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Chicago, Illinois • Indianapolis, Indiana • Rochester, Minnesota + 2 more

Conditions: Anterior Cruciate Ligament Reconstruction
Interventions: Body Weight Supported Treadmill Use of Patients with ACL Reconstruction; Other
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: Not listed
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Westerville, Ohio

Conditions: Cerebral Palsy, Brachial Plexus; Injury, Newborn
Interventions: Magnetoencephalography (MEG), Electroencephalography (EEG), Transcranial Magnetic Stimulation (TMS); Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 18 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Solid Pancreatic Mass Lesions, Malignant Neoplasm of Pancreas
Interventions: Novel 22-gauge Core Biopsy Needle + Standard Biopsy Needle; Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Obesity, Cancer
Interventions: simple goal setting, goal setting plus action intentions, goal setting plus coping intentions, goal setting plus action intentions plus coping intentions; Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 8 Years to 12 Years
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Depression, Anxiety
Interventions: Meru Health Program; Behavioral
Lead sponsor: Meru Health, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Sugary Beverages
Interventions: weSIPsmarter, weLearn2Read; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 2 Years and older
Enrollment: 744 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Christiansburg, Virginia

Conditions: Facial Defect
Interventions: cephalexin; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Effect of Diet on Breast Milk Composition
Interventions: Mediterranean Diet; Other
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Avascular Necrosis of the Talus, Talar Osteochondral Defect of Ankle, Talar Dysfunction
Interventions: Total Talus Replacement (TTR); Device
Lead sponsor: Restor3D; Industry
Eligibility: 22 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Stage II Squamous Cell Carcinoma of the Head and Neck, Stage III Squamous Cell Carcinoma of the Head and Neck, Stage IV Squamous Cell Carcinoma of the Head and Neck
Interventions: PD-L1 t-haNK cells, pembrolizumab, N-803; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Magnetic Resonance Imaging
Interventions: Gadobutrol (Gadavist, BAY86-4875); Drug
Lead sponsor: Bayer; Industry
Eligibility: Up to 2 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Savannah, Georgia • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
Interventions: Bcl-2 Inhibitor GDC-0199, Obinutuzumab, Ibrutinib, Pharmacological Study, Laboratory Biomarker Analysis, Quality-of-Life Assessment; Drug · Biological · Other
Lead sponsor: Kerry Rogers; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

Development of a Training Intervention to Improve Mental Health Treatment Effectiveness and Engagement for Youth With Documented Mental Health Disparities

To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.

A Home Program Using Multimodal Sensory Feedback for People With Parkinson Disease

Understanding Visual Confusion Using Stereoscopic Displays

Clinical Trial of Astaxanthin Formulation With Exercise in Sarcopenia Elderly

Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells

This Repeated Measures Parallel-group Investigation Will Examine the Influence of Short-term Melatonin Supplementation (5mg, 3 x Day for 72 Hours) on Cellular Responses, Functional Performance and Recovery Following an Acute Bout of Dynamic Resistance Exercise in Resistance Trained Men and Women

A Single Ascending Study of IOP Injection in Patients With Iron Deficient Anemia

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus

FK506 (Tacrolimus) in Pulmonary Arterial Hypertension

Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B

Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients

AlterG ACL Return to Running Case Series

Multi-modal Neuroimaging in Children With Cerebral Palsy or Brachial Plexus Birth Palsy

Comparison of a Novel 22-gauge Core Biopsy Needle

Squire's Quest! II: Implementation Intentions and Children's Fruit, Juice, and Vegetable (FJV) Consumption

Meru Health Program for Cancer Patients With Depression and Anxiety

weSIPsmarter: Evaluating a Digital Health Intervention Aimed at Reducing Sugary Drinks Among Rural Head Start Preschoolers and Their Parents

The Role of Antibiotics in Full Thickness Skin Graft Survival for Facial Reconstructive Surgery

A Dietary Intervention to Modify Breast Milk Content in Obese Lactating Women

Prospective Evaluation of Clinical and Radiographic Outcomes Following Total Talus Replacement (PROCLAIM)

Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)

Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia